Oxford University journal publishes new study on the homeopathic treatment of depression...

[Dana Ullman, MPH]

Dear Friends of Homeopathy,

This new study published in an Oxford University journal shows that
homeopathic treatment is as effective as Prozac in treating depression...and
is a lot safer. There is so much more research on homeopathy than most
people realize. People who want to know about the 200+ clinical trials in
homeopathy will benefit (greatly) by purchasing my eBook, "Homeopathic
Family Medicine: Evidence Based Nanopharmacology" --
http://www.homeopathic.com/store/hfm/ebook_hfm.jsp

"Q potencies" are the same as what some people refer to as "LM potencies"

http://ecam.oxfordjournals.org/cgi/reprint/nep114

Homeopathic Individualized Q-potencies versus Fluoxetine for Moderate to
Severe Depression: Double-blind, Randomized Non-inferiority Trial

U. C. Adler, N. M. P. Paiva, A. T. Cesar, M. S. Adler, A. Molina, A. E.
Padula and H. M. Calil

Homeopathy is a complementary and integrative medicine used in depression,
The aim of this study is to investigate the non-inferiority and tolerability
of individualized homeopathic medicines [Quinquagintamillesmial
(Q-potencies)] in acute depression, using fluoxetine as active control.
Ninety-one outpatients with moderate to severe depression were assigned to
receive an individualized homeopathic medicine or fluoxetine 20 mg day–1 (up
to 40 mg day–1) in a prospective, randomized, double-blind double-dummy
8-week, single-center trial. Primary efficacy measure was the analysis of
the mean change in the Montgomery & Asberg Depression Rating Scale (MADRS)
depression scores, using a non-inferiority test with margin of 1.45.
Secondary efficacy outcomes were response and remission rates. Tolerability
was assessed with the side effect rating scale of the Scandinavian Society
of Psychopharmacology. Mean MADRS scores differences were not significant at
the 4th (P¼0.654) and 8th weeks (P¼0.965) of treatment. Non-inferiority of
homeopathy was indicated because the upper limit of the confidence interval
(CI) for mean difference in MADRS change was less than the non-inferiority
margin: mean differences (homeopathy–fluoxetine) were 3.04 (95% CI 6.95,
0.86) and 2.4 (95% CI 6.05, 0.77) at 4th and 8th week, respectively. There
were no significant differences between the percentages of response or
remission rates in both groups. Tolerability: there were no significant
differences between the side effects rates, although a higher percentage of
patients treated with fluoxetine reported troublesome side effects and there
was a trend toward greater treatment interruption for adverse effects in the
fluoxetine group. This study illustrates the feasibility of randomized
controlled double-blind trials of homeopathy in depression and indicates the
non-inferiority of individualized homeopathic Q-potencies as compared to
fluoxetine in acute treatment of outpatients with moderate to severe
depression.
Dana Ullman, MPH
Homeopathic Educational Services
2124 Kittredge St.
Berkeley, CA. 94704
(510)649-0294
(800)359-9051 (orders only in the U.S.)
(510)649-1955 (fax)
dullman@igc.org OR dana@homeopathic.com
http://www.homeopathic.com